This project evaluates the potential of erb B-2/neu immunotherapy for neoplastic disease using DNA vaccines in mice transgenic for the non-activated rat neu oncogene. These mice uniformly develop mammary tumors that express high levels of neu, and thus serve as a model for patients with cancers that overexpress erb B-2, the human neu homologue. The investigators have made plasmid vectors encoding erb B-2 (pErb B-2) or rat neu (Pneu) that induce immune responses to erb B-2 or neu when injected into muscle (IM) or dermis (ID). The investigators have found that pNeu can induce protective immunity in FVB/N non-Tg mice from the adoptive transfer of otherwise syngeneic neu- expressing mammary tumors derived from FVB/N neu-Tg mice. However, they also find that FVB/N mice have an H-2 haplotype associated with a poor immune response potential to pErbB-2/neu DNA vaccines, arguably limiting their capacity to break self-tolerance to neu in FVB/N neu-Tg mice. They have bred the neu transgene onto strains of mice that have a high response potential to pErb B-2 and pNeu (e.g. BALB/c). Preliminary studies indicate that self-tolerance to neu can be broken in neu-Tg mice with the H-2d haplotype by ID injections of pErbB-2. Work done in parallel on this project has developed improved strategies for inducing desired immune responses against the antigens encoded by DNA vaccines. The investigators find that plasmids that encode chimeric antigens that are targeted for rapid proteasome-dependent degradation are significantly more efficient in inducing specific cytotoxic T lymphocyte ( CTL) responses than conventional DNA vaccines. In addition they have found that co-injection of a DNA vaccine with the plasmid encoding the CD40-ligand (CD154) can significantly improve the immune response to a transgene antigen. They will test whether these strategies enhance their ability to break self-tolerance to neu and induce protective immunity against de novo or adoptively transferred neu-expressing mammary tumors in neu-Tg mice. In addition they will compare the relative efficacy of such DNA vaccines strategies with that of using erbB-2/neu peptide-pulsed antigen presenting cells to induce CTL against syngeneic cells expressing high levels of the erb B-2/neu proto-oncogene.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
3R01CA066000-04S1
Application #
2867091
Study Section
Experimental Immunology Study Section (EI)
Program Officer
Hecht, Toby T
Project Start
1995-09-01
Project End
2000-06-30
Budget Start
1998-09-01
Budget End
1999-06-30
Support Year
4
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of California San Diego
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
077758407
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Burger, J A; Mendoza, R B; Kipps, T J (2001) Plasmids encoding granulocyte-macrophage colony-stimulating factor and CD154 enhance the immune response to genetic vaccines. Vaccine 19:2181-9
Burger, J A; Baird, S M; Powell, H C et al. (2000) Local and systemic effects after adenoviral transfer of the murine granulocyte-macrophage colony-stimulating factor gene into mice. Br J Haematol 108:641-52
Eling, D J; Johnson, P A; Sharma, S et al. (2000) Chronic lymphocytic leukemia B cells are highly sensitive to infection by herpes simplex virus-1 via herpesvirus-entry-mediator A. Gene Ther 7:1210-6
Hu, D; Kipps, T J (1999) Reduction in mitochondrial membrane potential is an early event in Fas-independent CTL-mediated apoptosis. Cell Immunol 195:43-52
Carter, J D; Neel, B G; Lorenz, U (1999) The tyrosine phosphatase SHP-1 influences thymocyte selection by setting TCR signaling thresholds. Int Immunol 11:1999-2014
Wu, Y; Nadler, M J; Brennan, L A et al. (1998) The B-cell transmembrane protein CD72 binds to and is an in vivo substrate of the protein tyrosine phosphatase SHP-1. Curr Biol 8:1009-17
Kato, K; Cantwell, M J; Sharma, S et al. (1998) Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J Clin Invest 101:1133-41
Siminovitch, K A; Neel, B G (1998) Regulation of B cell signal transduction by SH2-containing protein-tyrosine phosphatases. Semin Immunol 10:329-47
Mendoza, R B; Cantwell, M J; Kipps, T J (1997) Immunostimulatory effects of a plasmid expressing CD40 ligand (CD154) on gene immunization. J Immunol 159:5777-81
Wu, Y; Kipps, T J (1997) Deoxyribonucleic acid vaccines encoding antigens with rapid proteasome-dependent degradation are highly efficient inducers of cytolytic T lymphocytes. J Immunol 159:6037-43

Showing the most recent 10 out of 11 publications